Form 8-K

8-K — Electromed, Inc.

Accession: 0001437749-26-016422

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001488917

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — elmd20260213_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex_920785.htm)

EX-99.2 — EXHIBIT 99.2 (ex_920786.htm)

GRAPHIC (e01.jpg)

GRAPHIC (slide01.jpg)

GRAPHIC (slide03.jpg)

GRAPHIC (slide04.jpg)

GRAPHIC (slide05.jpg)

GRAPHIC (slide06.jpg)

GRAPHIC (slide07.jpg)

GRAPHIC (slide08.jpg)

GRAPHIC (slide09.jpg)

GRAPHIC (slide10.jpg)

GRAPHIC (slide11.jpg)

GRAPHIC (slide12.jpg)

GRAPHIC (slide13.jpg)

GRAPHIC (slide14.jpg)

GRAPHIC (slide15.jpg)

GRAPHIC (slide16.jpg)

GRAPHIC (slide17.jpg)

GRAPHIC (slide18.jpg)

GRAPHIC (slide19.jpg)

GRAPHIC (slide20.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: elmd20260213_8k.htm · Sequence: 1

elmd20260213_8k.htm

false

0001488917

2026-05-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 12, 2026

ELECTROMED, INC.

(Exact Name of Registrant as Specified in Its Charter)

Minnesota

001-34839

41-1732920

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification

Number)

500 Sixth Avenue NW

New Prague, MN 56071

(Address of Principal Executive Offices) (Zip Code)

(952) 758-9299

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.01 par value

ELMD

NYSE American LLC

(Title of each class)

(Trading Symbol)

(Name of each exchange on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On May 12, 2026, Electromed, Inc., a Minnesota corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 2.02.

Item 7.01

Regulation FD Disclosure.

The Company has updated its investor presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference into this Item 7.01. The Company intends to use the presentation in whole or in part, in one or more meetings with investors and analysts.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Number

Description

99.1

Press Release dated May 12, 2026

99.2

Company Investor Presentation dated May 12, 2026

104

Cover Page Interactive Data File (embedded in the cover page and formatted in inline XBRL)

The information contained in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ELECTROMED, INC.

Date: May 12, 2026

By:

/s/ Bradley M. Nagel

Name:

Bradley M. Nagel

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex_920785.htm · Sequence: 2

ex_920785.htm

Exhibit 99.1

Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter

18% Revenue growth and strong operating leverage exceeds consensus expectations for the third quarter of fiscal 2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and nine months ended March 31, 2026 (“Q3 FY 2026”).

Q3 FY 2026 Company Highlights

●

Net revenues increased 18.4% to a record $18.6 million in Q3 FY 2026, from $15.7 million in the third quarter of the prior fiscal year, led by an 18.6% increase in the core homecare market.

●

Operating income increased to a record $3.8 million, a 76.0% increase from the third quarter of the prior fiscal year, and 20.3% of net revenues.

●

Net income was a record $3.0 million, or $0.35 per diluted share, representing an increase of 58.8%, compared to $1.9 million, or $0.21 per diluted share in the third quarter of the prior fiscal year.

“I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected,” said Jim Cunniff, President and Chief Executive Officer. “We continue to make investments in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth."

Q3 FY 2026 Results

All amounts below are for the three months ended March 31, 2026, and compare to the three months ended March 31, 2025 (“Q3 FY 2025”).

Net revenues grew 18.4% to $18.6 million, from $15.7 million.

Revenue in our direct homecare business increased by 18.6% to $16.7 million, from $14.1 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per sales representative. Throughout Q3 FY 2026, we averaged 57 homecare direct field sales representatives. The annualized homecare revenue per weighted average direct sales representative in Q3 FY 2026 was $1,168,000, exceeding Electromed’s target range for the year of $1,000,000 to $1,100,000.

Non-homecare revenue was $1.8 million. Hospital revenue grew 42.5%, totaling $1.0 million. Homecare distributor revenue was $0.7 million, an increase of 2.7%. Other revenue of $0.1 million declined 40.7%.

Gross profit increased year-over-year to $14.6 million or 78.8% of net revenues from $12.2 million or 78.0% of net revenues. The increases in gross profit and gross margin were primarily a result of increased overall revenue and higher net revenues per device.

Selling, general and administrative (“SG&A”) expenses were $10.5 million, representing an increase of $0.7 million or 7.2%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average sales representative headcount and higher overall compensation costs.

Operating income was $3.8 million or 20.3% of net revenues, compared to $2.1 million, or 13.6% of net revenues. The 76.0% increase in operating income was primarily due to the increases in revenue and gross profit.

Net income increased by 58.8% to $3.0 million, or $0.35 per diluted share, compared to $1.9 million, or $0.21 per diluted share.

As of March 31, 2026, Electromed had $17.0 million in cash, $28.3 million in accounts receivable and no debt, achieving a working capital of $40.0 million and total shareholders’ equity of $49.2 million. The cash balance reflects an increase of $1.7 million for the nine months ended March 31, 2026, compared to a decrease in cash of $0.8 million in the nine months ended March 31, 2025. The increase in cash for the nine months ended March 31, 2026, was driven primarily by positive operating cash flow of $6.7 million, partially offset by share repurchases of $3.9 million of Electromed common stock.

Conference Call and Webcast Information

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, May 12, 2026.

Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1759896&tp_key=ae965d6622

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the Access ID 13760099. Additionally, an online replay of the webcast will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "continue,” “expect,” “may,” “potential,” “target,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases and changes to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Healthcare

(617) 877-9641

mike.cavanaugh@icrhealthcare.com

Source: Electromed, Inc.

Electromed, Inc.

Condensed Balance Sheets

March 31, 2026

June 30, 2025

(Unaudited)

Assets

Current Assets

Cash and cash equivalents

16,985,000

15,287,000

Accounts receivable (net of allowances for credit losses of $45,000)

28,251,000

24,660,000

Contract assets

1,086,000

1,036,000

Inventories

3,295,000

3,299,000

Income tax receivable

15,000

408,000

Prepaid expenses and other current assets

596,000

392,000

Total current assets

50,228,000

45,082,000

Property and equipment, net

5,209,000

4,714,000

Finite-life intangible assets, net

354,000

371,000

Other assets

1,221,000

1,173,000

Deferred income taxes

2,462,000

Total assets

59,474,000

53,802,000

Liabilities and Shareholders' Equity

Current Liabilities

Accounts payable

2,595,000

2,667,000

Accrued compensation

4,530,000

5,079,000

Warranty reserve

1,784,000

1,645,000

Other accrued liabilities

1,317,000

1,077,000

Total current liabilities

10,226,000

10,468,000

Other long-term liabilities

81,000

125,000

Total liabilities

10,307,000

10,593,000

Shareholders' Equity

Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,279,845 and 8,349,176 shares issued and outstanding, as of March 31, 2026, and June 30, 2025, respectively

83,000

Additional paid-in capital

23,949,000

21,941,000

Retained earnings

25,135,000

21,185,000

Total shareholders' equity

49,167,000

43,209,000

Total liabilities and shareholders' equity

59,474,000

53,802,000

Electromed, Inc.

Condensed Statements of Operations (Unaudited)

Three Months Ended

Nine Months Ended

March 31,

2026

2025

2026

2025

Net revenues

18,575,000

15,684,000

54,359,000

46,607,000

Cost of revenues

3,932,000

3,455,000

11,700,000

10,260,000

Gross profit

14,643,000

12,229,000

42,659,000

36,347,000

Operating expenses

Selling, general and administrative

10,516,000

9,812,000

31,617,000

29,033,000

Research and development

361,000

277,000

986,000

694,000

Total operating expenses

10,877,000

10,089,000

32,603,000

29,727,000

Operating income

3,766,000

2,140,000

10,056,000

6,620,000

Interest income, net

100,000

142,000

343,000

489,000

Net income before income taxes

3,866,000

2,282,000

10,399,000

7,109,000

Income tax expense

863,000

391,000

2,499,000

1,776,000

Net income

3,003,000

1,891,000

7,900,000

5,333,000

Income per share:

Basic

0.37

0.22

0.96

0.63

Diluted

0.35

0.21

0.91

0.59

Weighted-average common shares outstanding:

Basic

8,211,220

8,495,005

8,268,605

8,493,715

Diluted

8,647,794

8,967,838

8,673,345

8,980,218

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)

Nine Months Ended March 31,

2026

2025

Cash Flows From Operating Activities

Net income

7,900,000

5,333,000

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation

642,000

663,000

Amortization

162,000

112,000

Share-based compensation expense

1,960,000

2,409,000

Changes in operating assets and liabilities:

Accounts receivable

(3,591,000

)

(109,000

)

Contract assets

(50,000

)

(405,000

)

Inventories

(123,000

)

564,000

Prepaid expenses and other assets

(364,000

)

(779,000

)

Income tax receivable, net

393,000

(1,209,000

)

Accounts payable and accrued liabilities

291,000

877,000

Accrued compensation

(549,000

)

78,000

Net cash provided by operating activities

6,671,000

7,534,000

Cash Flows From Investing Activities

Expenditures for property and equipment

(1,033,000

)

(117,000

)

Expenditures for finite-life intangible assets

(44,000

)

(32,000

)

Net cash used for investing activities

(1,077,000

)

(149,000

)

Cash Flows From Financing Activities

Issuance of common stock upon exercise of options

268,000

381,000

Taxes paid on net share settlement of stock awards

(246,000

)

(2,278,000

)

Repurchase of common stock

(3,918,000

)

(6,331,000

)

Net cash used for financing activities

(3,896,000

)

(8,228,000

)

Net increase (decrease) in cash

1,698,000

(843,000

)

Cash and cash equivalents

Beginning of period

15,287,000

16,080,000

End of period

16,985,000

15,237,000

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: ex_920786.htm · Sequence: 3

Image Exhibit

Exhibit 99.2

Electromed, Inc. Investor Presentation May 12, 2026 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies

“Forward Looking Statements - Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases and changes to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.”

Electromed – Who We Are - Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. Key Stats: Headquarters: New Prague, MN Ticker: ELMD Manufacturing: Minnesota, USA Established: 1992 Treatment Focus: HFCWO Employees: 187* LTM Net Revenues: $71.8M* Market Cap: $193.8M* Cash / Debt: $17.0M / $0.0M* *As of and for the 12 months ended 03/31/2026

Electromed Highlights ● Growing and profitable medical technology company ● A leader in the large and expanding airway clearance market ● The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement. ● Attractive direct-to-patient and provider model ● Strong financial profile with attractive gross margins and well-capitalized balance sheet 35% Operating Income CAGR* *FY ‘21 through Q3 FY2026 TTM FY21: Operating Income: $3.1M Revenue: $35.8M FY22: Operating Income: $3.0M Revenue: $41.7M FY23: Operating Income: $4.0M Revenue: $48.1M FY24: Operating Income: $6.5M Revenue: $54.7M FY25: Operating Income: $9.7M Revenue: $64.0M TTM Q3’26: Operating Income: $13.1M Revenue: $71.8M

What is Bronchiectasis (BE)? BE is a condition that is prevalent, but underdiagnosed and often misdiagnosed ● Irreversible lung condition characterized by abnormal widening of one or more of the bronchi (airways) ● Repeated episodes of pulmonary inflammation and infection leads to mucus accumulating in the airways ● Mean prevalence of Bronchiectasis in patients with COPD is 54%¹ 1.Chalmers J. and Sethi S. Raising awareness of Bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18. Disease Misdiagnosed – Disease Underdiagnosed – HFCWO Under-prescribed Normal airways, lungs in cross-section, widened airways – normal airway – airway wall – muscle Airway with bronchiectasis – widened airway, mucus, scarred and thickened airway wall

U.S. Market: Large, Growing, Underpenetrated The Company is expanding awareness within the large BE patient population ~148K HFCWO Adopted - Estimated HFCWO Bronchiectasis penetration, treated population1 Bronchiectasis HFCWO penetration ~16%1 ~$2.8B - Estimated Revenue Opportunity for HFCWO Within Primary Pulmonology Callpoint2 ((923K – 148K) x 35% x $10.5K) = $2.8B2 ~923K U.S. BE Diagnosed - Estimated Net Bronchiectasis Prevalence, Diagnosed3 Diagnosed BE population has grown at ~12% annually3 4.1 Million U.S. Undiagnosed - Potential Total Addressable Market - $15.1B (4.1M x $10.5K) - Estimated Bronchiectasis Prevalence, Undiagnosed With COPD / BE Overlap4 35% of BE patients managed by pulmonologists3 1. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database, GUIDEHOUSE 2023 literature review and 2024 S2N HFCWO Claims data. 2. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 35% of BE patients managed by pulmonologists and $10.5K represents the assumed HFCWO ASP. 3. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 4. Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data.

How is Bronchiectasis Treated? HFCWO therapy mimics manual Chest Percussion Therapy (CPT) 1. Clear Airways FirstTM With SmartVest® 2. Treat The Infection (Antibiotics) 3. Reduce The Inflammation (Anti-Inflammatories) On average, HFCWO therapy is performed as follows: 2x per day, 30 minutes per session, 7 days a week How does SmartVest® HFCWO therapy work? Air-pulse technology – a generator delivers repeating pulses of air through a single hose to an inflated wearable vest. Gentle squeeze and release – each pulse gently squeezes and releases the chest to thin and loosen mucus in the lungs. Airway clearance – mucus is propelled upward toward major airways where it can be coughed and more easily. Airway clearance – smartvest – reduce inflammation – treat infection – complete bronchiectasis care

SmartVest ® Clearway HFCWO designed with the patient in mind SmartVest® has a well-established reimbursement code from CMS – E0483; the Company estimates it has over 270 million contracted lives in the U.S. An Enhanced Patient Experience - Sleek and lightweight generator - Intuitive user interface for better patient adherence - More portable and easier for travel

SmartNotes™ Patient Progress Report - Tracking patient outcomes and treatment progress to physicians SmartNotes combines patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management ● Telerespiratory Services: A team of Respiratory Therapists stay connected with patients and support their therapy utilization ● Outcomes Management: Easy-to-read report provides physicians with a comprehensive view of therapy impact

Clinical Evidence & Patient Satisfaction - HFCWO therapy is effective in treating BE patients “Therapy with SmartVest® significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function” - Powner 95% Of patients would recommend the SmartVest® to others3 97% Of patients report feeling better or the same after SmartVest® use3 98% Of patients report an increase in sputum production3 57% Reduction in antibiotic prescriptions1 59% Decrease in hospitalizations1 75% Fewer emergency department visits2 1. Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38. 2. Sievert CE, et al 2018. Incidence of Bronchiectasis-Related Exacerbation Rates After HFCWO Treatment—A Longitudinal Outcome-Based Study, Respiratory Therapy, 13(2), 38-41. 3. Patient data on file. “Therapy with HFCWO demonstrated key health outcomes improved in post- compared to pre-index period: cough, all-cause hospitalizations, pneumonia, and pulmonary hospitalizations” - DeKoven

Direct-to-Patient Model - Drives an attractive margin profile Electromed expects 78% gross margins to continue improving going forward Traditional Medical Equipment Channel: Manufacturer > Home Medical Equipment (HME) Distributor > Patient Direct-to-Patient Distribution (Electromed): Electromed > Patient

Net Revenue Breakdown - $71.8M (TTM ended 3/31/2026) By Setting: 94% Home Care (Includes $3.3 million from home care distributor revenue), 5% Hospitals, 1% Other Homecare by Payer: 50% Commercial/Other (Includes Managed Medicare and Managed Medicaid), 48% Medicare, 2% Medicaid Homecare Qualified Referral Volume: 73% Bronchiectasis, 20% Neuromuscular, 3% Cystic Fibrosis, 4% Other

Electromed Growth Strategy - Leveraging commercial team and reimbursement expertise to accelerate growth Electromed, Inc: ● Protect and grow homecare core o Protect and grow Homecare core with current strategy (sales force expansion, payor contracting, market development) as well as converting low prescribers to high prescribers and target high BE diagnosing physicians who are not prescribing SmartVest® ● Expand into natural adjacencies o Leverage existing technology platform – Pediatrics and Hospital (leveraging DTC and GPO contracts) ● Acquisition opportunities Explore potential inorganic acquisition opportunities

Long-Term Objectives, Electromed is committed to delivering long-term profitable growth Double-digit revenue growth: increase market share, deeper penetration of current SmartVest prescribers Operating margin improvement: operating leverage as revenue increases

Capital Allocation Strategy: Proven execution against the Company’s priorities Capital Allocation: Organic Business Growth > Generate Free Cash Flow > Potential Strategic Investments or Return to Shareholders FY2025 Execution: ● New CRM & CAPEX investments ● Sales rep expansion ● Market development ● Triple Down on BE campaign ● Product enhancements $10.0 million of shares repurchased in FY25

Why invest? Large, expanding chronic lung diseases market, clinically proven technology, broad payor coverage, consistent double-digit organic revenue growth, high gross margins, robust cash flow and expanding operating leverage

Performance vs. Russell Medical Equipment Index (TTM and as of 3/31/2026 Results): Sales Growth: ELMD 16.8% > RUS ME 12.8% Gross Margin: ELMD 78.4% > RUS ME 53.4% Operating Margin: ELMD 18.3% > RUS ME (7.0)%

Electromed, Inc.: Jim Cunniff, President & CEO, (952) 758-9299, jcunniff@electromed.com – Brad Nagel, CFO, (952) 758-9299, bnagel@electromed.com ICR Healthcare: Mike Cavanaugh, (617) 877-8641, mike.cavanaugh@icrhealthcare.com

Appendix

Financial Highlights (in $ millions, except share amounts)

Three Months Ended March 31, 2025 (unaudited): Revenues $15.7 Gross Profit $12.2 Gross Margin 78% Operating Income $2.1 Operating Margin 14% Net Income $1.9 Diluted EPS $0.21 Diluted Shares 8,967,838 Cash Provided by Operations $2.1

Three Months Ended March 31, 2026 (unaudited): Revenues $18.6 Gross Profit $14.6 Gross Margin 79% Operating Income $3.8 Operating Margin 20% Net Income $3.0 Diluted EPS $0.35 Diluted Shares 8,647,794 Cash Provided by Operations $3.5

Year Ended June 30, 2024: Revenues $54.7 Gross Profit $41.7 Gross Margin 76% Operating Income $6.6 Operating Margin 12% Net Income $5.2 Diluted EPS $0.58 Diluted Shares 8,864,585 Cash Provided by Operations $9.1

Year Ended June 30, 2025: Revenues $64.0 Gross Profit $50.0 Gross Margin 78% Operating Income $9.7 Operating Margin 15% Net Income $7.5 Diluted EPS $0.85 Diluted Shares 8,914,421 Cash Provided by Operations $11.4

TTM March 31, 2026 (unaudited): Revenues $71.8 Gross Profit $56.3 Gross Margin 78% Operating Income $13.1 Operating Margin 18% Net Income $10.1 Diluted EPS $1.17 Diluted Shares 8,647,794 Cash Provided by Operations $10.5

GRAPHIC

Filename: e01.jpg · Sequence: 8

Binary file (150947 bytes)

Download e01.jpg

GRAPHIC

Filename: slide01.jpg · Sequence: 9

Binary file (66144 bytes)

Download slide01.jpg

GRAPHIC

Filename: slide03.jpg · Sequence: 10

Binary file (111653 bytes)

Download slide03.jpg

GRAPHIC

Filename: slide04.jpg · Sequence: 11

Binary file (108737 bytes)

Download slide04.jpg

GRAPHIC

Filename: slide05.jpg · Sequence: 12

Binary file (164188 bytes)

Download slide05.jpg

GRAPHIC

Filename: slide06.jpg · Sequence: 13

Binary file (168219 bytes)

Download slide06.jpg

GRAPHIC

Filename: slide07.jpg · Sequence: 14

Binary file (140941 bytes)

Download slide07.jpg

GRAPHIC

Filename: slide08.jpg · Sequence: 15

Binary file (160249 bytes)

Download slide08.jpg

GRAPHIC

Filename: slide09.jpg · Sequence: 16

Binary file (157761 bytes)

Download slide09.jpg

GRAPHIC

Filename: slide10.jpg · Sequence: 17

Binary file (150711 bytes)

Download slide10.jpg

GRAPHIC

Filename: slide11.jpg · Sequence: 18

Binary file (96644 bytes)

Download slide11.jpg

GRAPHIC

Filename: slide12.jpg · Sequence: 19

Binary file (109093 bytes)

Download slide12.jpg

GRAPHIC

Filename: slide13.jpg · Sequence: 20

Binary file (122776 bytes)

Download slide13.jpg

GRAPHIC

Filename: slide14.jpg · Sequence: 21

Binary file (102629 bytes)

Download slide14.jpg

GRAPHIC

Filename: slide15.jpg · Sequence: 22

Binary file (121015 bytes)

Download slide15.jpg

GRAPHIC

Filename: slide16.jpg · Sequence: 23

Binary file (97591 bytes)

Download slide16.jpg

GRAPHIC

Filename: slide17.jpg · Sequence: 24

Binary file (69572 bytes)

Download slide17.jpg

GRAPHIC

Filename: slide18.jpg · Sequence: 25

Binary file (67290 bytes)

Download slide18.jpg

GRAPHIC

Filename: slide19.jpg · Sequence: 26

Binary file (22604 bytes)

Download slide19.jpg

GRAPHIC

Filename: slide20.jpg · Sequence: 27

Binary file (103114 bytes)

Download slide20.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 29

v3.26.1

Document And Entity Information

May 12, 2026

Document Information [Line Items]

Entity, Registrant Name

ELECTROMED, INC.

Document, Type

8-K

Document, Period End Date

May 12, 2026

Entity, Incorporation, State or Country Code

Entity, File Number

001-34839

Entity, Tax Identification Number

41-1732920

Entity, Address, Address Line One

500 Sixth Avenue NW

Entity, Address, City or Town

New Prague

Entity, Address, State or Province

Entity, Address, Postal Zip Code

56071

City Area Code

952

Local Phone Number

758-9299

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

ELMD

Security Exchange Name

NYSE

Entity, Emerging Growth Company

false

Amendment Flag

false

Entity, Central Index Key

0001488917

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration